CA2776778A1 - Peptides de parstatine - Google Patents

Peptides de parstatine Download PDF

Info

Publication number
CA2776778A1
CA2776778A1 CA2776778A CA2776778A CA2776778A1 CA 2776778 A1 CA2776778 A1 CA 2776778A1 CA 2776778 A CA2776778 A CA 2776778A CA 2776778 A CA2776778 A CA 2776778A CA 2776778 A1 CA2776778 A1 CA 2776778A1
Authority
CA
Canada
Prior art keywords
parstatin
ischemia
isolated peptide
angiogenesis
renal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2776778A
Other languages
English (en)
Inventor
Nikos Tsopanoglou
Michael Maragoudakis
Stanley Vinores
Jennifer Strande
Sotirios Gartaganis
Dimitrios Siablis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/645,991 external-priority patent/US8389476B2/en
Application filed by Individual filed Critical Individual
Publication of CA2776778A1 publication Critical patent/CA2776778A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2776778A 2009-10-01 2010-08-05 Peptides de parstatine Abandoned CA2776778A1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US24761109P 2009-10-01 2009-10-01
US57201809A 2009-10-01 2009-10-01
US12/572,018 2009-10-01
US61/247,611 2009-10-01
US12/645,991 US8389476B2 (en) 2007-03-29 2009-12-23 Parstatin peptides and uses thereof
US12/645,991 2009-12-23
PCT/IB2010/002142 WO2011039584A2 (fr) 2009-10-01 2010-08-05 Peptides

Publications (1)

Publication Number Publication Date
CA2776778A1 true CA2776778A1 (fr) 2011-04-07

Family

ID=46208927

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2776778A Abandoned CA2776778A1 (fr) 2009-10-01 2010-08-05 Peptides de parstatine

Country Status (4)

Country Link
EP (1) EP2483302A2 (fr)
AU (1) AU2010302383B2 (fr)
CA (1) CA2776778A1 (fr)
WO (1) WO2011039584A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101510941B1 (ko) 2012-07-03 2015-04-10 일양약품주식회사 신규한 펩타이드 및 이의 용도
WO2015173802A1 (fr) * 2014-05-11 2015-11-19 Tel Hashomer Medical Research Infrastructure And Services Ltd. Conjugués thérapeutiques à base de par-1 et utilisations correspondantes

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2277854T5 (es) * 1999-08-25 2011-02-04 Allergan, Inc. Neurotoxinas recombinantes activables.
US7811584B2 (en) * 2004-06-30 2010-10-12 Allergan, Inc. Multivalent clostridial toxins
US8227412B2 (en) * 2007-03-29 2012-07-24 Tsopanoglou Nikos E Bioactive parstatin peptides and methods of use
US20120088311A1 (en) * 2008-02-07 2012-04-12 Hadasit Medical Research Services & Development Limited Immuno-Detection of a Cancerous State in a Subject

Also Published As

Publication number Publication date
WO2011039584A2 (fr) 2011-04-07
WO2011039584A3 (fr) 2011-05-26
AU2010302383A1 (en) 2012-04-26
EP2483302A2 (fr) 2012-08-08
AU2010302383B2 (en) 2015-02-12

Similar Documents

Publication Publication Date Title
Azar Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis)
KR102268883B1 (ko) 누트린-3a 및 펩티드에 의한 폐 섬유증의 저해
Zhong et al. Protein S protects neurons from excitotoxic injury by activating the TAM receptor Tyro3–Phosphatidylinositol 3-Kinase–Akt pathway through its sex hormone-binding globulin-like region
AU6085700A (en) Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs
US8227412B2 (en) Bioactive parstatin peptides and methods of use
Zhou et al. Serine proteinase inhibitor SERPINA3K suppresses corneal neovascularization via inhibiting Wnt signaling and VEGF
US11266710B2 (en) Angio-3 for treatment of retinal angiogenic diseases
Rolfsen et al. Corneal neovascularization: a review of the molecular biology and current therapies
AU2010302383B2 (en) Parstatin peptides
US9180163B2 (en) Parstatin peptides
CA3035675C (fr) Composition pharmaceutique contenant un inhibiteur de mtor pour le traitement de la degenerescence maculaire
US8389476B2 (en) Parstatin peptides and uses thereof
US20230287430A1 (en) Use of pi3kc2b inhibitors for the preservation of vascular endothelial cell barrier integrity
US20180319868A1 (en) Serpin reactive center loop peptides and methods of use
JP7269649B2 (ja) Ｋｉｆ１３ｂ由来ペプチドおよび血管新生阻害方法
AU2015202449A1 (en) Parstatin peptides
US20150071909A1 (en) Methods and compositions for reducing the incidence of post-surgical adhesions
CA2555792A1 (fr) Administration therapeutique du peptide c16y anti-angiogenique brouille
US20230338483A1 (en) Method for the treatment of a disease using pigment epithelium-derived factor (pedf)
Lu et al. Therapeutic effects of a novel PIGF-1 derived peptide, ZY-1, on corneal neovascularization in vitro and in vivo
Fleischer et al. Direct neuronal protection by the protease‐activated receptor PAR4 antagonist ML354 after experimental stroke in mice
JP2020517714A (ja) 処置方法および新規構築物
Howell The role of thrombin and protease activated receptor-1 in the pathogenesis of pulmonary fibrosis
Passino Beyond the name: p75 neurotrophin receptor as a regulator of hepatic stellate cell differentiation in liver repair
EP1495766A1 (fr) Polypeptides dérivés de la protéase activatrice du facteur VII (FSAP) pour traiter les troubles liés à l'angiogénèse

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150730

FZDE Discontinued

Effective date: 20171109